Satellos Bioscience, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 12
- Market Cap
- -
- Website
- http://www.satellos.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Early Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Early Phase 1
1 (50.0%)Phase 2
1 (50.0%)A Long-term Follow-up Study for Participants That Completed the SAT-3247-CL-101 Study
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Satellos Bioscience, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06867107
- Locations
- 🇦🇺
St. Vincent Hospital, Melbourne, Victoria, Australia
First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort
Early Phase 1
Completed
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drug: matched placebo
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Satellos Bioscience, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT06565208
- Locations
- 🇦🇺
CMAX, Adelaide, South Australia, Australia
🇦🇺Veritus, Bayswater, Victoria, Australia
News
No news found